Interventional radiology

Joseph D. Inzinna, MD, DABR, is recognized by Continental Who's Who

Tuesday, January 19, 2021 - 8:40pm

The areas of specialty care offered include Body Imaging, Breast Imaging, Cardiovascular Imaging, Emergency Radiology, Interventional Radiology, Molecular Imaging, and more.

Key Points: 
  • The areas of specialty care offered include Body Imaging, Breast Imaging, Cardiovascular Imaging, Emergency Radiology, Interventional Radiology, Molecular Imaging, and more.
  • A graduate of the University of Bologna Medical School, Dr. Inzinna is a well-seasoned and board-certified radiologist having accrued 25 years of professional excellence in his field.
  • Additionally, he is also affiliated with MEDNAX, led by physicians to provide a network of specialists at your service.
  • Dr. Inzinna dedicates this honorable recognition to his mother, Monique Inzinna, and in the loving memory of his father and mentor, Joseph Inzinna.

Stents Market Revenue to Cross USD 14 Bn by 2026: Global Market Insights, Inc.

Tuesday, January 19, 2021 - 9:00am

SELBYVILLE, Del., Jan. 19, 2021 /PRNewswire/ --According to latest report "Stents Market by Product (Vascular Stents, Non-vascular Stents), Material (Metal, Polymer), Type, (Self-expandable Stents, Balloon-expandable Stents), End-use (Hospitals, Ambulatory Surgical Centers), Regional Outlook, Price Trends, Competitive Market Share & Forecast 2026", by Global Market Insights, Inc., the market valuation of stents will cross $14.3 billion by 2026.

Key Points: 
  • SELBYVILLE, Del., Jan. 19, 2021 /PRNewswire/ --According to latest report "Stents Market by Product (Vascular Stents, Non-vascular Stents), Material (Metal, Polymer), Type, (Self-expandable Stents, Balloon-expandable Stents), End-use (Hospitals, Ambulatory Surgical Centers), Regional Outlook, Price Trends, Competitive Market Share & Forecast 2026", by Global Market Insights, Inc., the market valuation of stents will cross $14.3 billion by 2026.
  • Rigorous RD activities by the manufacturers to develop innovative stents will be one of the key factors driving the stents market demand.
  • Polymer stent segment in the stents market is forecasted to reach USD 3 billion by 2026.
  • Self-expandable stents segment accounted for 36.1% of the market share in 2019 and is expected to exceed USD 5.3 billion by 2026.

Cardiovascular Systems, Inc. Receives CE Mark for Diamondback 360® Coronary Orbital Atherectomy System

Monday, January 18, 2021 - 9:05pm

Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today that it has received CE Mark for its Diamondback 360 Coronary Orbital Atherectomy System (OAS) and ViperWire Advance Coronary Guide Wire with Flex Tip (ViperWire Advance with Flex Tip).

Key Points: 
  • Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today that it has received CE Mark for its Diamondback 360 Coronary Orbital Atherectomy System (OAS) and ViperWire Advance Coronary Guide Wire with Flex Tip (ViperWire Advance with Flex Tip).
  • The Diamondback 360 Coronary OAS is the market-leading coronary atherectomy device in the United States.
  • We estimate 12 percent of percutaneous coronary intervention (PCI) patients present with significant calcific coronary disease.
  • Indications: The Diamondback 360 Coronary Orbital Atherectomy System (OAS) is a percutaneous orbital atherectomy system indicated to facilitate stent delivery in patients with coronary artery disease (CAD) who are acceptable candidates for PTCA or stenting due to de novo, severely calcified coronary artery lesions.

EU5 Biopsy Procedures Outlook Report 2020: Breast Biopsy Procedures, Colorectal Biopsy Procedures, Leukemia Biopsy Procedures and Others 2015-2025 - ResearchAndMarkets.com

Friday, January 15, 2021 - 10:47am

2.1 What Is This Report About?

Key Points: 
  • 2.1 What Is This Report About?
  • 4.1.6 Other Indications Biopsy Procedures, France, 2015-2025
    5.1.6 Other Indications Biopsy Procedures, Germany, 2015-2025
    6.1.6 Other Indications Biopsy Procedures, Italy, 2015-2025
    7.1.6 Other Indications Biopsy Procedures, Spain, 2015-2025
    8.1.6 Other Indications Biopsy Procedures, United Kingdom, 2015-2025
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210115005209/en/

NeoDynamics will be granted another European patent for its pulse biopsy tools

Thursday, January 14, 2021 - 7:41am

STOCKHOLM, Jan. 14, 2021 /PRNewswire/ -- NeoDynamics AB (Spotlight Stock Market: NEOD), a MedTech company dedicated to advancing diagnosis and care of breast cancer, today announces that the European Patent Office (EPO) has issued a Communication under Rule 71(3) EPC (Notice of Allowance) and intends to grant a European patent for NeoDynamics pulse biopsy tools, including a multi-purpose driver supporting several different needle options.

Key Points: 
  • STOCKHOLM, Jan. 14, 2021 /PRNewswire/ -- NeoDynamics AB (Spotlight Stock Market: NEOD), a MedTech company dedicated to advancing diagnosis and care of breast cancer, today announces that the European Patent Office (EPO) has issued a Communication under Rule 71(3) EPC (Notice of Allowance) and intends to grant a European patent for NeoDynamics pulse biopsy tools, including a multi-purpose driver supporting several different needle options.
  • The decision will be published in the European Patent Bulletin, once the requirements concerning the translation of the claims and payment of all fees are fulfilled by NeoDynamics.
  • "This is very exciting and supports our launch of the pulse biopsy system NeoNavia, including three needle options for all ultrasound led biopsy procedures.
  • Ultrasound guided biopsy in breast and axilla is perceived as critical to ensure an early and adequate diagnosis and ultimately improve patient outcomes".

NeoDynamics will be granted another European patent for its pulse biopsy tools

Thursday, January 14, 2021 - 7:40am

STOCKHOLM, Jan. 14, 2021 /PRNewswire/ -- NeoDynamics AB (Spotlight Stock Market: NEOD), a MedTech company dedicated to advancing diagnosis and care of breast cancer, today announces that the European Patent Office (EPO) has issued a Communication under Rule 71(3) EPC (Notice of Allowance) and intends to grant a European patent for NeoDynamics pulse biopsy tools, including a multi-purpose driver supporting several different needle options.

Key Points: 
  • STOCKHOLM, Jan. 14, 2021 /PRNewswire/ -- NeoDynamics AB (Spotlight Stock Market: NEOD), a MedTech company dedicated to advancing diagnosis and care of breast cancer, today announces that the European Patent Office (EPO) has issued a Communication under Rule 71(3) EPC (Notice of Allowance) and intends to grant a European patent for NeoDynamics pulse biopsy tools, including a multi-purpose driver supporting several different needle options.
  • The decision will be published in the European Patent Bulletin, once the requirements concerning the translation of the claims and payment of all fees are fulfilled by NeoDynamics.
  • "This is very exciting and supports our launch of the pulse biopsy system NeoNavia, including three needle options for all ultrasound led biopsy procedures.
  • Ultrasound guided biopsy in breast and axilla is perceived as critical to ensure an early and adequate diagnosis and ultimately improve patient outcomes".

Elixir Medical Announces First Patient Treated in BIOADAPTOR Randomized Controlled Trial of DynamX Coronary Bioadaptor System

Wednesday, January 13, 2021 - 1:00pm

Elixir Medical , a developer of innovative, drug-eluting cardiovascular devices, today announced that the first patient has been treated in the BIOADAPTOR randomized controlled trial (RCT) of the DynamX Coronary Bioadaptor System , the first drug-eluting coronary artery implant that adapts to vessel physiology.

Key Points: 
  • Elixir Medical , a developer of innovative, drug-eluting cardiovascular devices, today announced that the first patient has been treated in the BIOADAPTOR randomized controlled trial (RCT) of the DynamX Coronary Bioadaptor System , the first drug-eluting coronary artery implant that adapts to vessel physiology.
  • We are enthusiastic about leading this trial studying an important innovation in percutaneous coronary interventions, the bioadaptor, said Dr. Saito.
  • The DynamX Bioadaptor RCT is an important contribution to demonstrating the significant benefits our device offers for patients, said Motasim Sirhan, Elixir Medical CEO.
  • Final 5-Year Follow-Up of a Randomized Controlled Trial of Everolimus- and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice.

Endospan Enrolls First Patient in the TRIOMPHE IDE Study

Tuesday, January 12, 2021 - 2:00pm

Endospan , a pioneer in off-the-shelf endovascular repair of aortic arch disease, announces the first implant of the NEXUS Aortic Arch Stent Graft System on a patient with a thoracic aortic aneurysm as part of the TRIOMPHE Study in Norfolk, Virginia, January 11, 2021.

Key Points: 
  • Endospan , a pioneer in off-the-shelf endovascular repair of aortic arch disease, announces the first implant of the NEXUS Aortic Arch Stent Graft System on a patient with a thoracic aortic aneurysm as part of the TRIOMPHE Study in Norfolk, Virginia, January 11, 2021.
  • The TRIOMPHE Study is a multi-arm, multi-center, non-randomized, prospective, clinical study to evaluate the safety and effectiveness of NEXUS in treating thoracic aortic lesions involving the aortic arch.
  • With the first patient enrolled in the TRIOMPHE IDE study, Endospan marks the next crucial milestone towards US approval for the NEXUS Aortic Arch Repair Stent Graft System, said Kevin Mayberry, CEO.
  • The NEXUS is specifically engineered for total endovascular arch repair to address the specific challenges of the aortic arch anatomy.

Lower-Profile Web Intrasaccular Aneurysm Treatment Device Receives FDA Approval

Tuesday, January 12, 2021 - 12:00pm

The WEB System is a unique, single-device treatment solution for wide neck bifurcation aneurysms in a new category of devices called intrasaccular flow disruptors.

Key Points: 
  • The WEB System is a unique, single-device treatment solution for wide neck bifurcation aneurysms in a new category of devices called intrasaccular flow disruptors.
  • When placed inside the aneurysm sac, the WEB device's proprietary microbraid technology bridges the aneurysm neck, disrupting blood flow, and creates a scaffold for long-lasting treatment.
  • "The excellent clinical results we can achieve with intrasaccular flow disruption technology has changed the way we approach the treatment of wide neck bifurcation aneurysms, and the WEB 17 System expands upon that.
  • When placed inside the aneurysm sac, the WEB device's proprietary microbraid technology bridges the aneurysm neck, disrupting blood flow, and creates a scaffold for long-lasting treatment.

Peripheral Stent Implants Market to Close in on US$ 6 Bn by 2030, Driven by Increasing Peripheral Artery Disease Patient Pool Worldwide - Persistence Market Research

Tuesday, January 12, 2021 - 12:01pm

Further, rising adoption of vascular stenting procedures is also surging demand for peripheral stents, propelling the growth of the global peripheral stent implants market.

Key Points: 
  • Further, rising adoption of vascular stenting procedures is also surging demand for peripheral stents, propelling the growth of the global peripheral stent implants market.
  • The global peripheral stent implants market is expected to exhibit a healthy CAGR of nearly 7% over the forecast period (20202030).
  • Higher peripheral artery disease patient pool and increasing adoption of peripheral vascular stents in Asian countries are expected to propel market growth in the region.
  • Get Full Access of Report: https://www.persistencemarketresearch.com/checkout/32225
    Manufactures in the peripheral stent implants market are actively focusing on launching new products to hold a better position in the peripheral stent implants market.